#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 drugs in pediatric obesity
Liraglutide and semaglutide carry regulatory approval for adolescents with obesity. A 2026 review maps what the trials found and what gaps remain.
Incretin drugs for T2D: 2026 NMA results
A 2026 network meta-analysis of 102 trials and 98,693 T2D patients ranked tirzepatide first for glycaemic control and retatrutide first for weight loss.
How semaglutide works: the GLP-1 receptor
Semaglutide binds the GLP-1 receptor in the pancreas, brain, and gut. Here is what happens at each site.
Semaglutide side effects: what trials show
The STEP and SUSTAIN programmes documented semaglutide adverse events at scale. Here is what the data show, from GI effects to the thyroid boxed warning.
Sex differences in semaglutide muscle loss
A July 2026 study finds female ob/ob mice are protected from semaglutide-induced muscle loss while males are not. What the finding means and what it does not.
ONWARDS 8: icodec plus semaglutide in T2D
ONWARDS 8 found that adding weekly semaglutide to weekly insulin icodec cut HbA1c by 1.23 points and body weight by 3.85 kg, with low hypoglycaemia rates.
Tirzepatide, CAVI, and arterial stiffness
A 2026 retrospective cohort found tirzepatide reduced CAVI from borderline to normal, alongside weight loss and glycaemic improvements, over 12.7 months.
Dapagliflozin plus semaglutide: BMI classes
A 328-patient Saudi cohort: proportional BMI response to dapagliflozin is uniform across obesity classes; semaglutide add-on helps most in class I.
GLP-1 drugs and micronutrient risk
How GLP-1 receptor agonists and dual incretin drugs create vitamin and mineral gaps, which nutrients are most at risk, and what monitoring looks like.
GLP-1 neuro research: what 20 years shows
A 2026 bibliometric analysis mapped 1,202 publications on GLP-1 receptor agonists in neurodegenerative disease from 2006 to 2025.
Incretins after bariatric surgery
A US cohort of 208,155 post-bariatric patients: tirzepatide beat semaglutide on weight loss (17.2% vs 12.0%). No significant cardiovascular signal either way.
Orforglipron for sleep apnea: ATTAIN-OSA
ATTAIN-OSA is testing an oral GLP-1 pill against sleep apnea. Here is what the 712-participant protocol measures and how it compares to SURMOUNT-OSA.